← All indications
Lupus Erythematosus, Discoid
A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
Subtype terms (1)
More specific conditions that are subtypes of Lupus Erythematosus, Discoid in the MeSH hierarchy.
Drugs by status
Organizations
Organization Involved with Phase 2 Indications (15)
- Celgene
- Immunomedics
- Pfizer
- Novartis
- Astion Pharma A/S
- Rigel Pharmaceuticals
- National Cancer Institute (NCI)
- Harvard University
- Florida Academic Dermatology Centers
- New York University
- University of Leeds
- University of Rochester
- Department of Defense
- National Institute for Health Research, United Kingdom
- Leo Pharma
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (2)